相关临床试验
246
26 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1858
已完成
126
51.2%
尚未招募
26
10.6%
招募中
88
35.8%
暂停
2
0.8%
终止
1
0.4%
Unknown
2
0.8%
撤回
1
0.4%
暂无批准数据
- A study published in GeroScience identifies beta-2-microglobulin (B2M) and cystatin C as blood-based biomarkers that predict future disability in adults aged 85–89 years. - Higher levels of B2M and cystatin C were associated with significantly greater disability risk (hazard ratios of 1.35 and 1.42, respectively), independent of age, sex, kidney function, and lifestyle factors. - Findings were independently validated in the Italian InCHIANTI aging study, particularly among participants aged 80 and older, supporting cross-population generalizability. - Because both proteins are measurable with standard clinical assays, they could enable earlier preventive interventions such as exercise, nutritional support, and rehabilitation.
- Japanese researchers demonstrate that local injections of adipose-derived mesenchymal stem cells effectively reduce inflammation in ocular graft-versus-host disease, offering a safer alternative to corticosteroids. - The study reveals that stem cell treatment increases regulatory T cells and enhances tissue healing, with injected cells naturally clearing within a week, minimizing long-term complications. - Researchers at Fujita Health University report successful localized therapy effects in mouse models, setting the stage for potential human clinical trials of this targeted treatment approach.
